Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interspecies scaling of suprachoroidal drug delivery using ocular geometry and drug physicochemical properties.

Scientific reports·2026
Same author

Cysteamine-eluting contact lenses: integrating in vitro, in vivo, and in silico approaches for ocular drug delivery.

International journal of pharmaceutics·2025
Same author

British anti-Lewisite (BAL) reduces the severity of systemic and local responses of the eye after exposure to the chemical warfare agent surrogate for Lewisite, phenylarsine oxide (PAO).

Toxicology reports·2025
Same author

Can contact lenses deliver drugs to the back of the eye?

Therapeutic delivery·2025
Same author

Rose Bengal-Assisted Photodynamic Antimicrobial Therapy for Keratitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025
Same author

Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025

Related Experiment Video

Updated: Jul 7, 2026

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

Ophthalmic light sensitive nanocarrier systems.

Jennifer G Christie1, Uday B Kompella

  • 1Department of Pharmaceutical Sciences, 985840 Nebraska Medical Center, Omaha, NE 68198-5840, United States.

Drug Discovery Today
|February 16, 2008
PubMed
Summary
This summary is machine-generated.

Photodynamic therapy (PDT) offers a novel treatment for chronic eye neovascular disorders. This approach uses light-activated agents to treat conditions like macular degeneration and diabetic retinopathy effectively.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation
12:00

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation

Published on: February 24, 2016

Related Experiment Videos

Last Updated: Jul 7, 2026

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation
12:00

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation

Published on: February 24, 2016

Area of Science:

  • Ophthalmology
  • Biomedical Engineering
  • Photochemistry

Background:

  • Chronic neovascular eye disorders, including age-related macular degeneration and proliferative diabetic retinopathy, cause significant vision impairment.
  • Current treatments for these conditions are limited, necessitating innovative therapeutic strategies.
  • Photodynamic therapy (PDT) has emerged as a promising treatment modality for ocular neovascularization.

Purpose of the Study:

  • To review current clinical applications of photodynamic therapy (PDT) for eye diseases.
  • To discuss essential components and desirable characteristics of PDT agents and light sources.
  • To explore emerging investigational nanosystems and colloidal carriers for enhanced PDT efficacy.

Main Methods:

  • Review of existing clinical photodynamic therapy (PDT) protocols for ophthalmic conditions.
  • Analysis of photosensitizer properties, light delivery systems, and carrier formulations.
  • Examination of novel nanosystems and colloidal carriers investigated for PDT applications.

Main Results:

  • Summary of currently available clinical PDTs for neovascular eye diseases.
  • Identification of key features for effective photosensitizers and light sources.
  • Overview of investigational nanosystems and colloidal carriers enhancing PDT delivery and efficacy.

Conclusions:

  • Photodynamic therapy (PDT) is a valuable and evolving treatment for neovascular eye disorders.
  • Optimizing photosensitizers, light sources, and delivery systems, including nanosystems, is crucial for improving PDT outcomes.
  • Continued research into novel PDT approaches holds significant potential for vision preservation.